FDA clears Bayer's MR injection system for ultra-high-field imaging

Bayer announced Tuesday that the U.S. Food and Drug Administration granted 510(k) clearance for expanded capabilities of its MEDRAD MRXperion Magnetic Resonance Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments.

The updated clearance expands MRXperion's labeled field strength compatibility to support magnetic resonance imaging scanners with magnetic fields up to and including 7 Tesla, offering radiology departments greater flexibility within diverse MR suite configurations. It also introduces Imaging Scanner Interface 2 capability, which enables communication between the injector and scanner system, helping streamline exam coordination and support operational efficiency.

"MRXperion already has a strong track record of delivering dependable imaging performance across clinical settings, and this clearance reinforces and expands on its established reputation as a flexible solution that supports coordinated, efficient workflows across MR systems," said Jill Carbone, vice president and head of Radiology North America Product & Pipeline at Bayer. "The clearance also exemplifies our continued innovation in MR solutions to consistently meet the needs of today's imaging providers."

MR systems are deployed across healthcare settings with differing technical and workflow requirements. MRXperion is engineered to support this full spectrum of use, from routine clinical imaging to advanced research applications.

MEDRAD MRXperion is a piston-technology power injector used to deliver contrast agents and saline during contrast-enhanced MRI procedures. The system supports streamlined workflow, point-of-care efficiency and injection data management.

MRI is a noninvasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues.

Recent Advances in MR Contrast Injection Technology

The medical imaging industry has witnessed significant technological progress in MR contrast injection systems over the past several years, driven by evolving clinical demands and the increasing complexity of imaging protocols.

Ultra-high-field MRI scanners operating at 7 Tesla and above have gained traction in research institutions and select clinical centers, requiring injection equipment that can function reliably in these powerful magnetic environments. These advanced scanners offer enhanced image resolution and diagnostic capabilities, particularly for neurological and musculoskeletal imaging, but demand specialized supporting equipment that can withstand extreme magnetic field strengths.

Industry manufacturers have focused on developing injector systems with improved scanner integration capabilities, allowing automated communication between imaging equipment and contrast delivery systems. These advances reduce manual steps during examinations, minimize the potential for protocol errors and support more consistent imaging outcomes across different facilities and operators.

Workflow optimization has emerged as a critical priority, with newer injection systems incorporating features such as enhanced data management, remote operation capabilities and simplified user interfaces. These improvements address persistent challenges in radiology departments facing increased examination volumes and pressure to reduce scan times while maintaining image quality.

Safety features have also advanced, with modern systems incorporating more sophisticated monitoring of injection parameters, improved detection of potential complications and enhanced fail-safe mechanisms. Some systems now offer dual-syringe configurations supporting complex multi-phase imaging protocols that require precise timing and coordination between contrast and saline delivery.

The integration of artificial intelligence and machine learning into imaging workflows has begun influencing injection system design, with manufacturers exploring automated protocol selection and adaptive injection parameters based on patient-specific factors. These developments align with broader healthcare trends toward personalized medicine and precision diagnostics.